AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,512.00GBp
3:04am EST
Price Change (% chg)

63.00p (+1.42%)
Prev Close
4,449.00p
Open
4,507.00p
Day's High
4,544.00p
Day's Low
4,500.00p
Volume
75,375
Avg. Vol
2,684,746
52-wk High
4,946.41p
52-wk Low
3,367.07p

AZN.L

Chart for AZN.L

About

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments... (more)

Overall

Beta: 0.41
Market Cap (Mil.): £56,313.82
Shares Outstanding (Mil.): 1,262.89
Dividend: 53.10
Yield (%): 3.78

Financials

  AZN.L Industry Sector
P/E (TTM): 86.42 37.01 37.62
EPS (TTM): 0.52 -- --
ROI: 2.60 18.05 17.39
ROE: 4.71 18.84 18.30
Search Stocks

AstraZeneca first-in-class ovarian cancer drug wins EU approval

LONDON - AstraZeneca's all-important cancer drug business received a fillip on Thursday as a new medicine against ovarian cancer was approved in Europe, making it the first of its kind to reach the market.

2:46am EST

AstraZeneca first-in-class ovarian cancer drug wins EU approval

LONDON, Dec 18 - AstraZeneca's all-important cancer drug business received a fillip on Thursday as a new medicine against ovarian cancer was approved in Europe, making it the first of its kind to reach the market.

2:40am EST

BRIEF-Astrazeneca's Lynparza gets EU approval

* Lynparza approved in European Union as first-in-class treatment for advanced BRCA-mutated ovarian cancer Source text for Eikon: Further company coverage:

2:14am EST

AstraZeneca, Nektar constipation drug wins European approval

LONDON - AstraZeneca's new drug for the treatment of opioid-induced constipation, which was developed with Nektar Therapeutics, has been approved in the European Union, the British company said on Tuesday.

09 Dec 2014

AstraZeneca, Nektar constipation drug wins European approval

LONDON, Dec 9 - AstraZeneca's new drug for the treatment of opioid-induced constipation, which was developed with Nektar Therapeutics, has been approved in the European Union, the British company said on Tuesday.

09 Dec 2014

BRIEF-Astrazeneca's Moventig treatment approved in the EU

* Moventig  approved in european union for opioid-induced constipation Source text for Eikon: Further company coverage:

09 Dec 2014

AstraZeneca, Ranbaxy prevail in Nexium antitrust trial

- A Massachusetts jury has found that an agreement between AstraZeneca Plc and Ranbaxy Laboratories Ltd to delay the launch of a generic version of AstraZeneca's heartburn drug Nexium was not anticompetitive.

08 Dec 2014

AstraZeneca, Ranbaxy prevail in Nexium antitrust trial

Dec 5 - A Massachusetts jury has found that an agreement between AstraZeneca Plc and Ranbaxy Laboratories Ltd to delay the launch of a generic version of AstraZeneca's heartburn drug Nexium was not anticompetitive.

05 Dec 2014

AstraZeneca and Lilly move Alzheimer's drug into big trial

LONDON - AstraZeneca and Eli Lilly said on Monday they had started a large trial of their experimental Alzheimer's drug, seen as a promising, but still risky, approach for slowing the memory-robbing disease.

01 Dec 2014

AstraZeneca and Lilly move Alzheimer's drug into big trial

LONDON, Dec 1 - AstraZeneca and Eli Lilly said on Monday they had started a large trial of their experimental Alzheimer's drug, seen as a promising, but still risky, approach for slowing the memory-robbing disease.

01 Dec 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$125.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks